Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Respiratory infection cases surge 124% amid haze

Health ministry says 17 areas recorded unhealthy air quality at 8am today.

Respiratory infection cases surge 124% amid haze

The health ministry reported a significant rise in respiratory infection cases, particularly upper respiratory tract infections (URTI) and asthma, due to the ongoing haze affecting multiple regions across the country. URTI cases surged by 124.4%, from 1,637 in the 32nd epidemiological week to 3,674 in the subsequent week. Likewise, asthma cases jumped by an alarming 259%, climbing from 61 to 219 instances. However, there was a slight decrease in conjunctivitis cases, from 157 to 146.

Although the number of areas experiencing unhealthy air quality has decreased from 31 on August 25 to 17 at 8am today, the haze persists in certain parts of Sarawak, while other regions seem to have more transient haze conditions. The ministry has pledged to continue monitoring haze-related illnesses to assess the impact on the health of residents in the affected areas.

Currently, only five locations have recorded unhealthy air quality: Samarahan, Serian, and Sri Aman in Sarawak; Cheras in Kuala Lumpur; and Johan Setia in Selangor.

Written by urgent.news from Free Malaysia Today's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Also reported by 1 other outlet

Read the original at freemalaysiatoday.com →

More in Health & Medicine

Teaching the immune system what to fight - and what to spare

Two health announcements landed 48 hours apart last week, and hardly anyone connected them. On Monday, the Emirates Drug Establishment approved a once-daily pill for non-segmental vitiligo, the condition that causes patches of skin to lose their colour. No regulator anywhere had licensed an oral treatment for these patients.

Daewoong Secures U.S. Patent for Ionizable Lipid

Daewoong Pharmaceutical said on Aug. 27 that the U.S. Patent and Trademark Office (USPTO) had notified the company of its decision to grant a patent for ionizable lipid-related technology, a core original technology of the lipid nanoparticle (LNP) delivery platform “eTurna,” which it acquired from U

  • Daewoong Pharmaceutical receives USPTO confirmation for ionizable lipid patent on August 27.
  • Patent covers ionizable lipid structures in eTurna LNP delivery platform.
  • Acquisition of Turn Biotechnologies assets strengthens Daewoong's mRNA therapeutics position.

More from Thursday 27 August →